Biotransformation of the anti-angiogenic compound SU5416

Drug Metabolism and Disposition

Volumn 28, Issue 12, 2000, Pages 1505-1512

  Antonian, Lida ^a   Zhang, Hongbing ^a   Yang, Cheng ^a   Wagner, Greg ^a   Shawver, Laura K ^a   Shet, Manjunath ^b,c   Ogilvie, Brian ^b   Madan, Ajay ^b   Parkinson, Andrew ^b  

^a SUGEN INC   (United States)

^b XenoTech LLC   (United States)

^c PURDUE PHARMA L P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOGENESIS INHIBITOR; DRUG METABOLITE;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOG; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; MALE; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; GLUCURONIDES; HUMANS; INDOLES; MACACA FASCICULARIS; MICE; MICROSOMES, LIVER; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET;

ANIMALIA; CANIS FAMILIARIS;

EID: 0033669345     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Angingenesis in malignancies of the female genital tract
2. New Paradigms for the treatment of cancer: The role of anti-angiogenesis agents
3. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates
4. PK and PD of SU5416 in a phase I, dose-escalating trial in patients with advanced malignancies
5. Molecular and biological properties of vascular endothelial growth factor
6. Angiogenesis in cancer, vascular, rheumatoid and other disease
7. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
8. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
9. Partial purification of cytochrome P450 and cytochrome P-448 from rat liver microsomes
10. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
11. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
12. Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites
13. Vascular endothelial growth factor (VEGF) and its receptors
14. Effects of freezing, thawing and storing human liver microsomes on P450 activity
15. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies
16. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor (VEGF) receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
17. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases
18. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy
19. Angiogenesis and tumor metastasis